4//SEC Filing
Dupret Daniel 4
Accession 0001415889-18-001122
CIK 0001604191other
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 11:57 AM ET
Size
13.9 KB
Accession
0001415889-18-001122
Insider Transaction Report
Form 4
Dupret Daniel
Chief Scientific Officer
Transactions
- Award
Common Stock
2018-07-12+15,000→ 15,000 total - Award
Options
2018-07-12+60,000→ 60,000 totalExercise: $3.04Exp: 2023-06-28→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]Represents grant of restricted stock. Shares shall vest in increments as follows: 7,500 shares upon the acceptance of a U.S. IND for MS1819, and 7,500 shares upon the the first CF patient dosed with MS1819 anywhere in the globe.
- [F2]Options with respect to 30,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 30,000 shares vest upon the the first CF patient dosed with MS1819 anywhere in the globe.
Documents
Issuer
AzurRx BioPharma, Inc.
CIK 0001604191
Entity typeother
Related Parties
1- filerCIK 0001680916
Filing Metadata
- Form type
- 4
- Filed
- Jul 17, 8:00 PM ET
- Accepted
- Jul 18, 11:57 AM ET
- Size
- 13.9 KB